McAdam LLC’s Insys Therapeutics, Inc. INSY Stock Holding History

McAdam LLC’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-193	Closed	-$2K	–	719
2018 Q3	$2K	Hold	193	–	–	﹤0.01%	554
2018 Q2	$1K	Buy	193 +65	+51%	+$453	﹤0.01%	619
2018 Q1	$1K	Buy	+128	New	+$1.06K	﹤0.01%	742

Other funds holding INSY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

McAdam LLC's INSY Position: Q4 2018 in Review

McAdam LLC sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 193 shares — an estimated $2K sold.

McAdam LLC first reported a position in INSY in Q1 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

McAdam LLC reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 193 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $2K.
McAdam LLC first reported a position in Insys Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
McAdam LLC's Insys Therapeutics, Inc. position peaked at $2K in Q3 2018.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.